Classifications: central nervous system agent; cerebral stimulant; anorexiant
Pregnancy Category: X
Controlled Substance: Schedule III
25 mg, 50 mg tablets
Indirect acting sympathomimetic amine with amphetamine-like actions but with fewer side effects than amphetamine.
Anorexiant effect thought to be secondary to stimulation of hypothalamus to release stored catecholamines in the CNS.
Short-term adjunct in management of exogenous obesity.
Known hypersensitivity to sympathomimetic amines; angle-closure glaucoma; advanced arteriosclerosis, angina pectoris, severe
cardiovascular disease, moderate to severe hypertension; hyperthyroidism, agitated states; history of drug abuse; children
<12 y; lactation. Safe use during pregnancy (category X) is not established.
Diabetes mellitus; older adults; psychosis.
Adult: PO 2550 mg 13 times/d
CNS: Euphoria, irritability, hyperactivity, nervousness, restlessness, insomnia, tremor, headache, light-headedness, dizziness, depression following stimulant effects. CV:
Palpitation, tachycardia, elevated BP, irregular heart beat. GI: Xerostomia, nausea, vomiting, diarrhea or constipation, abdominal cramps. Chronic Intoxication: Marked insomnia, irritability, hyperactivity, personality changes, psychosis, severe dermatoses.
sodium bicarbonate decrease amphetamine elimination; ammonium chloride,
ascorbic acid increase amphetamine elimination; barbiturates may antagonize the effects of both drugs; furazolidone may increase BP effects of amphetamines, and interaction may persist for several weeks after discontinuation of furazolidone;
guanadryl antagonize antihypertensive effects; because mao inhibitors, selegiline can cause hypertensive crisis (fatalities reported); do not administer amphetamines during or within 14 d of these drugs; phenothiazines may inhibit mood-elevating effects of amphetamines; tricyclic antidepressants enhance amphetamine effects because they increase norepinephrine release; beta agonists increase amphetamine's adverse cardiovascular effects.
Absorption: Readily absorbed from GI tract. Duration: 4 h. Elimination: Renal elimination.
- Give as a single daily dose, preferably midmorning or midafternoon, according to patient's eating habits.
- Schedule daily dose no later than 6 h before patient retires to avoid insomnia.
- Store in tight, light-resistant containers at 15°30° C (59°86° F) unless otherwise directed.
Assessment & Drug Effects
- Assess for signs of excessive CNS stimulation: insomnia, restlessness, tremor, palpitations. These may indicate need for dosage
- Monitor vital signs; report elevated BP, tachycardia, and irregular heart rhythm.
- Monitor diabetics for loss of glycemic control.
Patient & Family Education
Note: Anorexiant effects are temporary and tolerance may occur; long-term use is not indicated.
- Do not drive or engage in potentially hazardous activities until response to drug is known.
- Do not terminate high dosage therapy abruptly; GI distress, stomach cramps, trembling, unusual tiredness, weakness, and mental
depression may result.
- Do not breast feed while taking this drug.